<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Theravance Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/theravance-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(THRX) Theravance Third Quarter Loss Deteriorates</title>
		<link>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313</link>
		<comments>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:01:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[FF]]></category>
		<category><![CDATA[First Opportunity Fund Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICS]]></category>
		<category><![CDATA[Morgan Stanley Insured California Municipal Securi]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86313</guid>
		<description><![CDATA[Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was attributable to a lukewarm top-line performance as well as increased research and development (R&#38;D) expenses. Revenue at Theravance though up 21.3% over the prior year to $6.4 million was below the Zacks Consensus Estimate of $7 million. The Quarter in Detail Revenues for the quarter primarily consisted of the amortization of deferred revenues received under the company’s collaborations with Astellas Pharma and GlaxoSmithKline plc (GSK). Theravance earned a royalty of $0.8 million on Vibativ sales from Astellas Pharma on net sales of $4.5 million. Vibativ, Theravance’s only commercialized drug, is an injectable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76322</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:03:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76253</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Reports Earnings In Line With Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/04/thrx-theravance-reports-earnings-in-line-with-estimates/73180</link>
		<comments>http://www.stockbloghub.com/2011/05/04/thrx-theravance-reports-earnings-in-line-with-estimates/73180#comments</comments>
		<pubDate>Wed, 04 May 2011 16:46:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73180</guid>
		<description><![CDATA[Theravance Inc.’s (THRX) first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 35 cents per share. Earnings improvement was driven by better top-line performance. Revenue at Theravance increased 10% over the prior year to $6.3 million due to higher royalty revenue from Vibativ sales in the reported quarter. Revenue was however below the Zacks Consensus Revenue Estimate of $7 million. The Quarter in Detail Revenues for the quarter primarily consisted of the amortization of deferred revenues received under the company’s collaborations with Astellas Pharma and GlaxoSmithKline plc (GSK). Theravance earned a royalty of $0.6 million on Vibativ sales from Astellas Pharma on net sales of $3.5 million. Vibativ is marketed by Astellas Pharma in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/thrx-theravance-reports-earnings-in-line-with-estimates/73180/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204</link>
		<comments>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204#comments</comments>
		<pubDate>Sat, 02 Apr 2011 15:18:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70204</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company&#8217;s fourth quarter and fiscal year 2010 financial results. Theravance’s fourth quarter 2010 loss per share of 25 cents was narrower than both the Zacks Consensus Estimate for a loss of 28 cents and the year-ago loss of 35 cents per share. The earnings improvement was driven by a better top-line performance and lower research and development costs. Revenue at Theravance increased more than 80% over the prior year to $6.9 million. Revenue was also slightly above the Zacks Consensus Revenue Estimate of $6 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest potential in the company’s pipeline, which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Third Quarter 2010 Earnings Loss Wider Than Expected</title>
		<link>http://www.stockbloghub.com/2010/10/25/thrx-theravance-third-quarter-2010-earnings-loss-wider-than-expected/56418</link>
		<comments>http://www.stockbloghub.com/2010/10/25/thrx-theravance-third-quarter-2010-earnings-loss-wider-than-expected/56418#comments</comments>
		<pubDate>Tue, 26 Oct 2010 04:44:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=56418</guid>
		<description><![CDATA[Theravance Inc.’s (THRX) third quarter 2010 loss per share of $0.29 was $0.02 wider than the Zacks Consensus Estimate, but narrower than the year-ago quarter loss of $0.35. Revenue at Theravance decreased 3.9% to $5.3 million. Revenue also missed the Zacks Consensus Revenue Estimate of $7 million. Revenues for the quarter primarily consisted of the amortization of deferred revenues received under its collaborations with Astellas and GlaxoSmithKline plc (GSK). This was partially offset by the write-off of $0.82 million Vibativ (telavancin) inventory that is no longer realizable. Theravance earned a royalty of $0.42 million on Vibativ from Astellas Pharma on net sales of $2.3 million. Vibativ is indicated for the treatment of complicated skin and skin structure infections (cSSSI). Operating expenses slipped 5.4% to $25.2 million. General and administrative (G&#38;A) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/25/thrx-theravance-third-quarter-2010-earnings-loss-wider-than-expected/56418/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Reports Wider Loss Than Forecast</title>
		<link>http://www.stockbloghub.com/2010/04/22/thrx-theravance-reports-wider-loss-than-forecast/34655</link>
		<comments>http://www.stockbloghub.com/2010/04/22/thrx-theravance-reports-wider-loss-than-forecast/34655#comments</comments>
		<pubDate>Thu, 22 Apr 2010 19:46:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34655</guid>
		<description><![CDATA[Theravance (THRX) reported first quarter fiscal 2010 loss per share of 35 cents, 7 cents more than the Zacks Consensus Estimate and worse than the loss of 29 cents in the year-ago period. Theravance earns revenues in the form of milestone payments from its partners including GlaxoSmithKline (GSK) and Astellas Pharma. Revenues were $5.7 million during the quarter compared with $9.5 million in the first quarter of 2009. Last year’s revenues included the recognition of deferred revenue of $4.2 million associated with the company&#8217;s long-acting muscarinic antagonist program, the rights to which were returned by Glaxo. Operating expenses for the quarter remained almost unchanged at $26.8 million. While R&#38;D expenses increased 4%, G&#38;A expenses came down 8.2% primarily due to lower employee-related costs. R&#38;D expenses in the corresponding year-ago period ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/thrx-theravance-reports-wider-loss-than-forecast/34655/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Begins Phase II Mid-stage Trial</title>
		<link>http://www.stockbloghub.com/2010/04/15/thrx-theravance-begins-phase-ii-mid-stage-trial/33983</link>
		<comments>http://www.stockbloghub.com/2010/04/15/thrx-theravance-begins-phase-ii-mid-stage-trial/33983#comments</comments>
		<pubDate>Thu, 15 Apr 2010 17:40:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33983</guid>
		<description><![CDATA[Theravance (THRX) began a phase II “proof of concept&#8221; clinical trial for one of its pipeline candidates, TD-1211. The drug, an orally-administered peripherally selective mu opioid receptor antagonist (PUMA), is being studied to evaluate its effectiveness, tolerability and safety in patients with opioid-induced constipation (OIC). Results from studies of TD-1211 on healthy volunteers have shown that the drug was well tolerated at all doses administered. The phase II study is looking to evaluate the constipation-relieving effects, safety and tolerability of the drug in patients who have been experiencing constipation during a chronic opioid therapy. The trial, to be conducted on 50 patients, will be randomized so that patients receive either TD-1211 (orally once daily dosage) or placebo along with their opioid treatment for over 14 days. The primary endpoint of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/15/thrx-theravance-begins-phase-ii-mid-stage-trial/33983/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Offers 7.5 Million Shares</title>
		<link>http://www.stockbloghub.com/2010/03/19/thrx-theravance-offers-7-5-million-shares/31361</link>
		<comments>http://www.stockbloghub.com/2010/03/19/thrx-theravance-offers-7-5-million-shares/31361#comments</comments>
		<pubDate>Fri, 19 Mar 2010 22:47:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31361</guid>
		<description><![CDATA[Theravance (THRX) has decided to raise funds by offering 7.5 million shares. Net proceeds are expected to be utilized for general corporate purposes including research expenses and debt reduction. However, the offer will increase the number of outstanding shares by 12%. We believe the need for additional funds has arisen primarily due the advancement of the company’s Relovair Program in collaboration with GlaxoSmithKline (GSK). The program, currently in phase III studies, aims to develop a next generation combination treatment for patients with chronic obstructive pulmonary disease (COPD) and asthma. The phase III program, to be conducted with more than 6,000 patients, is designed to evaluate the safety and effectiveness of the addition of a long-acting beta2 agonist (LABA) to an inhaled corticosteroid (ICS) in patients suffering from COPD. Enrollment has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/19/thrx-theravance-offers-7-5-million-shares/31361/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance&#8217;s Earnings Report Misses Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/14/thrx-theravances-earnings-report-misses-estimates/28020</link>
		<comments>http://www.stockbloghub.com/2010/02/14/thrx-theravances-earnings-report-misses-estimates/28020#comments</comments>
		<pubDate>Sun, 14 Feb 2010 22:21:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28020</guid>
		<description><![CDATA[During the fourth quarter of 2009, Theravance’s (THRX) loss per share came in at 35 cents, missing the Zacks Consensus Estimate by two cents and worse than the loss of 26 cents reported in the year-ago period. Revenues were $3.8 million during the quarter compared with $5.9 million in the fourth quarter of 2008. For the full year of 2009, Theravance reported revenues and loss per share of $24.4 million and $1.35, respectively. Theravance earns revenues in the form of milestone payments from its collaborating partners including GlaxoSmithKline (GSK) and Astellas Pharma. Operating expenses for the quarter increased 15.8% year-over-year at $24.8 million. R&#38;D expenses were 21% higher primarily due to a $4.9 million reimbursement of development expenses received from Astellas Pharma in the fourth quarter of 2008, partially offset ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/14/thrx-theravances-earnings-report-misses-estimates/28020/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson and Johnson Suffers Another Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014</link>
		<comments>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014#comments</comments>
		<pubDate>Thu, 31 Dec 2009 18:24:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24014</guid>
		<description><![CDATA[Johnson and Johnson (JNJ) has received yet another setback related to its pipeline candidate ceftobiprole, a broad-spectrum antibiotic ? aiming the methicillin-resistant Staphylococcus aureus (MRSA) ? for the treatment of complicated skin infections and nosocomial pneumonia. Johnson and Johnson had licensed the drug from Swiss drug company Basilea Pharmaceuticals in 2005. Johnson and Johnson received a complete response letter (CRL) from the US Food and Drug Administration (FDA), delaying the approval process further. According to the FDA, there were many flaws in the trials due to which the company has been asked to conduct new studies to evaluate the drug&#8217;s safety and effectiveness. Johnson and Johnson intends to discuss its future course of action related to ceftobiprole with the FDA shortly. The new drug application (NDA) for ceftobiprole has been ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/31/jnj-johnson-and-johnson-suffers-another-pipeline-setback/24014/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Gets Major Setback From FDA</title>
		<link>http://www.stockbloghub.com/2009/11/30/thrx-theravance-gets-major-setback-from-fda/21551</link>
		<comments>http://www.stockbloghub.com/2009/11/30/thrx-theravance-gets-major-setback-from-fda/21551#comments</comments>
		<pubDate>Tue, 01 Dec 2009 00:40:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21551</guid>
		<description><![CDATA[Theravance (THRX) received a major setback in the approval process of Vibativ (telavancin) for the treatment of nosocomial pneumonia (NP). Recently, the company received a complete response letter (CRL) regarding this from the US Food and Drug Administration (FDA). Although the original Prescription Drug User Fee Act (PDUFA) date was Nov 26, 2009, the company had earlier indicated that the approval would be extended to the next year. As per the CRL, Theravance will have to submit additional data and analyses for the NP patient population. While the telavancin NP clinical trials included clinical response as the primary endpoint and all-cause mortality as a secondary endpoint, the FDA has asked the company to evaluate data with all-cause mortality as the primary efficacy endpoint. In addition, the CRL issued by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/30/thrx-theravance-gets-major-setback-from-fda/21551/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Earnings Post Loss Wider Than Expected</title>
		<link>http://www.stockbloghub.com/2009/10/28/thrx-thrx-loss-wider-than-expected-analyst-blog/19065</link>
		<comments>http://www.stockbloghub.com/2009/10/28/thrx-thrx-loss-wider-than-expected-analyst-blog/19065#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:19:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19065</guid>
		<description><![CDATA[Theravance (THRX) announced its third quarter results after the closing bell yesterday. The company’s loss per share came in at 35 cents, a penny wider than the Zacks Consensus Estimate. It had earned 34 cents per share in the year-ago period. Revenues were $5.5 million during the quarter, compared with $6 million in prior-year quarter. Theravance receives revenues in the form of milestone payments from its collaborating partners including GlaxoSmithKline (GSK) and Astellas Pharma. Operating expenses remained unchanged at $26.6 million. While R&#38;D expenses declined 2.6% due to lower costs related to the regulatory process for telavancin (Vibativ), G&#38;A expenses increased 8.7% due to higher employee related costs. The reported quarter had been quite significant for Theravance with the company receiving US Food and Drug Administration (FDA) approval for its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/thrx-thrx-loss-wider-than-expected-analyst-blog/19065/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Earns Milestone Payment</title>
		<link>http://www.stockbloghub.com/2009/10/26/thrx-theravance-earns-milestone-payment/18785</link>
		<comments>http://www.stockbloghub.com/2009/10/26/thrx-theravance-earns-milestone-payment/18785#comments</comments>
		<pubDate>Mon, 26 Oct 2009 23:39:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18785</guid>
		<description><![CDATA[Recently, Theravance (THRX) received a milestone payment of $20 million from its partner Astellas Pharma. The payment follows the U.S. Food and Drug Administration (FDA) approval of Vibativ (telavancin) and for supplying Astellas Pharma with the launch inventory for the first commercial sale of the drug in the U.S. Vibativ is expected to hit the U.S. market by year-end. Earlier, in September, Theravance received FDA approval to market Vibativ for the treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria. While the drug will be marketed and sold by Astellas, Theravance will receive royalties on global sales. In the U.S. , the company will help Astellas in marketing the drug for the first three years post approval. Apart from cSSSI, Vibativ is also being studied for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/26/thrx-theravance-earns-milestone-payment/18785/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Earns FDA Approval for Skin Infection Drug</title>
		<link>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265</link>
		<comments>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265#comments</comments>
		<pubDate>Wed, 16 Sep 2009 16:22:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[Viropharma Incorporated]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15265</guid>
		<description><![CDATA[In a quantum achievement, Theravance (THRX) received approval from the US Food and Drug Administration (FDA) to market its Vibativ (telavancin) for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria. Vibativ, jointly developed with Japan’s Astellas Pharma, is expected to hit the US market by end of this year. While the drug will be marketed and sold by Astellas, Theravance will receive royalties on global sales. In the U.S., the company will help Astellas in marketing the drug for the first three years post approval. Apart from cSSSI, Vibativ is also being studied for hospital-acquired pneumonia (HAP). The company has already submitted a New Drug Application (NDA) for this indication and has been assigned a Prescription Drug User Fee Act (PDUFA) date of Nov. 26. The approval ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/thrx-theravance-earns-fda-approval-for-skin-infection-drug/15265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2009/09/14/frx-forest-laboratories-presents-encouraging-data/15099</link>
		<comments>http://www.stockbloghub.com/2009/09/14/frx-forest-laboratories-presents-encouraging-data/15099#comments</comments>
		<pubDate>Mon, 14 Sep 2009 17:32:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Forest Laboratories]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15099</guid>
		<description><![CDATA[We are pleased to hear that Forest Laboratories (FRX) presented encouraging data from its phase III trial of ceftaroline for the treatment of community-acquired pneumonia [CAP] in hospitalized patients. The company presented new data from two multicenter studies – FOCUS 1 and FOCUS 2 – at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. In addition to CAP, ceftaroline is also being studied for complicated skin and skin structure infections (cSSSI) caused by gram-positive bacteria. The randomized, double-blind trial compared ceftaroline with ceftriaxone in hospitalized adult patients with moderate to severe CAP. Following both the trials, it was found that patients treated with ceftaroline demonstrated a better cure rate (84.3%) compared to those treated with ceftriaxone (77.7%). In addition, the overall microbiological response rate in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/14/frx-forest-laboratories-presents-encouraging-data/15099/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Johnson &amp; Johnson Responds to FDA Questions on Antibiotic Drug Trials</title>
		<link>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144</link>
		<comments>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:39:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals]]></category>
		<category><![CDATA[Forest Laboratories]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[Viropharma Incorporated]]></category>
		<category><![CDATA[VPHM]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14144</guid>
		<description><![CDATA[We are pleased to hear that the US Food and Drug Administration (FDA) has accepted Johnson &#38; Johnson’s (JNJ) response on clinical trial-related issues. Last month, the agency had warned the company for not maintaining proper records during the trial of ceftobiprole, a broad-spectrum antibiotic for the treatment of complicated skin infections and nosocomial pneumonia. J&#38;J had licensed the drug from Swiss drugmaker Basilea Pharmaceuticals in 2005. The issue must be resolved for the drug to be approved. The new drug application for ceftobiprole has been pending since May 2007. The approval is getting delayed since protocol-related issues have been present from the initial stages. In November last year, the FDA issued a Complete Response letter stating that it could not approve the new drug application at that time as ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/jnj-johnson-johnson-responds-to-fda-questions-on-antibiotic-drug-trials/14144/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

